The Study Of Vascular Endothelial Growth Inhibitor 151 Recombinant Adenoviruses Combined With Dexamethasone Suppressing Corneal Transplantation Rejection

Objective To evaluate the probability of vascular endothelial growth inhibitor 151 ( VEGI₁₅₁ ) recombinant adenoviruses combined with dexamethasone on suppressing heterolamellar corneal transplantation rejection . Methods VEGI₁₅₁ gene was cloned into adenovirus vector and then packed in 293A cell to makeAd-VEGI₁₅₁. Inflammatory corneal neovascularization ( CNV ) models and heterolamellar corneal transplantation models in rabbits were established. The therapeutic effects of Ad-VEGIisi on CNV and Ad -VEGI₁₅₁ combined with dexamethasone on xenograft rejection were observed respectively. Results The study showed that Ad-VEGI₁₅₁ could express functional protein and could inhibit the growth of CNV significantly. Both the rejection index and the xenograft rejection rate in the Ad-VEGI₁₅₁ combined with dexamethasone group were statistically lower than that in other groups of xenografts. Conclusions The results suggest that Ad-VEGIisi could inhibit the growth of CNV significantly. The topical application of Ad -VEGI151 combined with dexamethasone suppressed effectively the postoperative xenograft rejection rate of heterolamellar corneal transplantation .